Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs

Mino, Naoko; A, Iio; Hamamoto, Ken

doi:10.1002/1097-0142(19880815)62:4<730::aid-cncr2820620415>3.0.co;2-w

Cited by 79 publications

(44 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The serum level of SCCA is increased in parallel to the growth of the tumour size or the recurrence of the disease. Therefore, measurement of the serum level of SCCA has been used clinically for the diagnosis and the management of SCC of the uterine cervix as well as other various organs (Kato et al, 1982(Kato et al, , 1983Maruo et al, 1985;Mino et al, 1988;Brioschi et al, 1991).…”

mentioning

confidence: 99%

Squamous cell carcinoma antigen suppresses radiation-induced cell death

et al. 2001

View full text Add to dashboard Cite

Summary Previous study has demonstrated that squamous cell carcinoma antigen (SCCA) 1 attenuates apoptosis induced by TNFα, NK cell or anticancer drug. In this study, we have examined the effect of SCCA2, which is highly homologous to SCCA1, but has different target specificity, against radiation-induced apoptosis, together with that of SCCA1. We demonstrated that cell death induced by radiation treatment was remarkably suppressed not only in SCCA1 cDNA-transfected cells, but also in SCCA2 cDNA-transfected cells. In these transfectants, caspase 3 activity and the expression of activated caspase 9 after radiation treatment were suppressed. Furthermore, the expression level of phosphorylated p38 mitogen-activated protein kinase (p38 MAPK) was suppressed compared to that of the control cells. The expression level of upstream stimulator of p38 MAPK, phosphorylated MKK3/MKK6, was also suppressed in the radiation-treated cells. Thus, both SCCA1 and SCCA2 may contribute to survival of the squamous cells from radiation-induced apoptosis by regulating p38 MAPK pathway.

show abstract

mentioning

confidence: 99%

Squamous cell carcinoma antigen suppresses radiation-induced cell death

et al. 2001

View full text Add to dashboard Cite

show abstract

“…This was confirmed in the present study when the conventional RIA method was used for the assay of TA-4: the positive ratio was less than 50% in SCC of the oesophagus, head and neck (Table I). In addition, even in SCC of the lung, the positive ratio was low in the early stages of the disease (Mino et al, 1988) (see also Table II). The major finding in the present study is that the limitation of the diagnostic usefulness could be considerably overcome by using the new assay method of IRMA.…”

Section: Discussionmentioning

confidence: 60%

“…The positive ratios assessed as the percentage of patients with serum TA-4 higher than the normal range were, for example, 75% and 59% in SCC of the uterus and the lung, respectively. However, as reported previously (Mino et al, 1988), its diagnostic usefulness seemed rather limited in SCC of other organs, such as the oesophagus, head and neck. This was confirmed in the present study when the conventional RIA method was used for the assay of TA-4: the positive ratio was less than 50% in SCC of the oesophagus, head and neck (Table I).…”

Section: Discussionmentioning

confidence: 67%

“…Previously, we measured serum TA-4 in patients with SCC of various organs including the lung, oesophagus, maxillary sinus and oral cavity and demonstrated that TA-4 is a useful marker for SCC not only of the uterine cervix but also of these organs, especially in evaluating therapeutic effects and monitoring recurrence (Mino et al, 1988). In the previous study, however, we also found that the serum TA-4 level and the positive ratio (the percentage of patients with serum TA-4 levels higher than the normal range) were not so high in the early stages of these diseases and even in the advanced stages in SCC of the tongue, larynx and pharynx, suggesting that its use in these cases was limited.…”

mentioning

confidence: 99%

See 1 more Smart Citation

An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay

Mino-Miyagawa

Kimura²,

Hamamoto³

1990

Br J Cancer

View full text Add to dashboard Cite

Summary The serum level of tumour-antigen 4 (TA-4) was measured in 181 patients with squamous cell carcinoma (SCC) of various organs (71 lung, 24 uterus, 16 oesophagus, 64 head and neck and six skin), 34 patients with other types of lung cancer and 35 patients with benign diseases. To compare the results with those obtained by the conventional competitive radioimmunoassay (RIA) using a polyclonal antibody, a new immunoradiometric assay (IRMA) method was used which has recently been developed using two monoclonal antibodies raised to different epitopes of TA-4. Both methods provided essentially the same results: the serum TA-4 levels were high in patients with SCC of various organs when compared with those of healthy controls and patients with other types of lung cancer or benign diseases. However, the positive ratios assessed as the percentage of patients with elevated serum TA-4 levels were higher with the IRMA method than with the RIA method in SCC of all organs, as much as 2-3 times higher in SCC of the larynx, tongue and pharynx. In contrast, in patients with benign diseases or other types of lung cancer, there was no difference in the positive ratios between the two methods. This was largely due to the improvement in sensitivity and accuracy of assay with the new method, which resulted in a decrease in the normal value in healthy controls. It was concluded that with the new IRMA method using monoclonal antibodies, the diagnostic detectability of serum TA-4 is enhanced in SCC of all organs.Since the initial report of Kato and Torigoe (1977), it has been established that tumour-antigen 4 (TA-4), a protein fraction purified from squamous cell carcinoma (SCC) tissue of the uterine cervix, is a useful marker for uterine cervical SCC (Kato et al., 1979(Kato et al., , 1982(Kato et al., , 1983 Maruo et al., 1985). Previously, we measured serum TA-4 in patients with SCC of various organs including the lung, oesophagus, maxillary sinus and oral cavity and demonstrated that TA-4 is a useful marker for SCC not only of the uterine cervix but also of these organs, especially in evaluating therapeutic effects and monitoring recurrence (Mino et al., 1988). In the previous study, however, we also found that the serum TA-4 level and the positive ratio (the percentage of patients with serum TA-4 levels higher than the normal range) were not so high in the early stages of these diseases and even in the advanced stages in SCC of the tongue, larynx and pharynx, suggesting that its use in these cases was limited. This limitation may be due to, in part at least, the sensitivity and accuracy of the assay method used: the competitive conventional radioimmunoassay (RIA) method using a polyclonal antibody.Recently, monoclonal antibodies for TA-4 were obtained and an immunoradiometric sandwich assay (IRMA) method using two monoclonal antibodies was developed (Dainabot Co. Ltd, Tokyo, Japan) (Ikeda, 1987). Using the newly developed IRMA method, in the present study, we measured the serum TA-4 levels in healthy controls and in patients...

show abstract

“…7 Several studies have shown that increased serum SCCA levels are seen in SCC patients 8,9 and correlate with the extent of disease in patients with SCC, 10,11 although the protein itself is not detected in adenocarcinomas. 6 In a previous study, it was reported that this tumor marker could be separated into two fractions (a neutral form and an acidic form).…”

Section: Introductionmentioning

confidence: 99%

Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer

et al. 2006

View full text Add to dashboard Cite

Squamous cell carcinoma antigens SCCA1 and SCCA2 are highly homologous serine proteinase inhibitors which have been widely utilized as serological markers for squamous cell cancers, but it has recently been demonstrated that only SCCA2 is truly specific for certain forms of lung cancer. Using a construct containing the 5 0 -flanking region of the SCCA2 gene between À460 and þ 0 bp and the luciferase reporter gene, SCCA2 promoter activity was detected in SCCA2-producing SCC cell lines (LK-2, LC-1), but not in SCCA2-nonproducing lung adenocarcinoma cell lines (A549, ABC-1, and RERF-LC-MS) or normal cells (WI-38, SAEC, and NHEKAdult). Infection with a recombinant adenovirus vector, Ad-SCCA2-DsRed, resulted in cell-specific expression of the SCCA2 promoter-driven DsRed marker gene only in LK-2 and LC-1 cells. The same strategy was used for SCCA2-driven expression of a proapoptotic gene, (KLAKLAK)2, which can cause mitochondrial disruption by triggering mitochondrial permeabilization and swelling, resulting in the release of cytochrome c and induction of apoptosis. Infection with Ad-SCCA2-KLAKLAK2 specifically reduced the growth of the two human lung SCC cell lines compared to the SCCA2 nonproducing cell lines both in vitro and in vivo, suggesting that the SCCA2 promoter had a tumor-specific effect. These results suggest that transduction of SCCA2 promotercontrolled suicide genes by adenoviral vectors can confer transcriptionally targeted cytotoxicity in SCCA2-producing lung SCC cells, and represents a novel strategy for gene transfer specifically targeted to SCC in the lung. Cancer Gene Therapy ( IntroductionLung carcinoma is the most common malignant neoplasm and represents the leading cause of cancer death in the developed world. 1 Among lung carcinomas, adenocarcinoma and squamous cell carcinoma (SCC) are the most frequently encountered forms. Despite the use of optimal chemotherapy and radiotherapy regimens, there has been little improvement in the prognosis of these cancer patients during the last decade. 2,3 This underscores the need to seek novel therapeutic modalities for lung cancer patients. One such approach is gene therapy by administration of vectors expressing cytotoxic genes; however, in order to maximize tumor-killing efficacy and minimize any potential adverse effects of this approach, it would be advantageous to employ a cancer-specific targeting strategy. For adenocarcinomas in general, transcriptional targeting by the use of cancer-specific promoters such as the carcinoembryonic antigen (CEA) promoter has been described previously. 4,5 However, little has been reported for SCC-specific regulation.The squamous cell carcinoma antigen (SCCA) was first reported by Kato et al. 6 in 1977 as a circulating tumor marker for SCC, particularly that of cervix, head and neck, esophagus, and lung. 7 Several studies have shown that increased serum SCCA levels are seen in SCC patients 8,9 and correlate with the extent of disease in patients with SCC, 10,11 although the protein itself is not detected in adenoca...

show abstract

Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs

Cited by 79 publications

References 6 publications

Squamous cell carcinoma antigen suppresses radiation-induced cell death

Squamous cell carcinoma antigen suppresses radiation-induced cell death

An immunoradiometric assay of tumour-antigen 4 (TA-4): a comparison with conventional radioimmunoassay

Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer

Contact Info

Product

Resources

About